Transcenta Reports First Patient Dosing in P-I Study of TST002 for the Treatment of Osteoporosis in China
Shots:
- The first patient has been dosed in the P-I study to evaluate the safety, tolerability, and PK profile of TST002 in patients with osteoporosis
- The P-II clinical studies of Blosozumab in the US and Japan showed a promising safety profile and efficacy data. Additionally, Transcenta gets the license rights to develop and commercialize Blosozumab in Greater China in 2019
- TST002 is a humanized anti-sclerostin mAb for the treatment of osteoporosis and other bone loss diseases. The therapy showed anabolic & anti-resorptive effects that stimulates bone formation & inhibits bone absorption thus resulting in a fast increase in bone mineral density & bone strength
Ref: PRNewswire | Image: Transcenta
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
